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Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain. Lomustine is a nitrosurea that
crosses the blood brain barrier and there is evidence to suggest that temozolomide may reverse resistance to lomustine. A
multicentre phase I/II study was conducted to assess the maximum-tolerated dose (MTD), safety and efficacy of the combination of
temozolomide and lomustine in melanoma metastatic to the brain. Increasing doses of temozolomide and lomustine were
administered in phase I of the study to determine the MTD. Patients were treated at the MTD in phase II of the study to six cycles,
disease progression or unacceptable toxicity. Twenty-six patients were enrolled in the study. In phase I of the study, the MTD was
defined as temozolomide 150mgm
 2 days 1–5 every 28 days and lomustine 60mgm
–2 on day 5 every 56 days. Dose-limiting
neutropaenia and thrombocytopaenia were observed at higher doses. Twenty patients were treated at this dose in phase II of the
study. No responses to therapy were observed. Median survival from starting chemotherapy was 2 months. The combination of
temozolomide and lomustine in patients with brain metastases from melanoma does not demonstrate activity. The further evaluation
of this combination therefore is not warranted.
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Metastatic melanoma generally has a poor prognosis and few
effective systemic treatment options. The median survival for
patients with this disease is 6–9 months although 10–20% of
patients will survive for 5 years (Balch et al, 2001). The
intravenously administered alkylating agent dacarbazine (DTIC)
is a standard treatment for metastatic melanoma with single agent
response rates reported in the range of 5–15% (Falkson et al, 1998;
Chapman et al, 1999; Middleton et al, 2000; Avril et al, 2004).
The brain is a common site of metastasis in melanoma and the
standard treatment for brain metastases is radiotherapy although
surgery has a role in selected patients. Dacarbazine is generally
ineffective at treating brain metastases from melanoma although a
response rate of 7% with a further 29% of patients experiencing
disease stabilisation has been reported with the related orally
administered alkylating agent temozolomide as a single agent
(Agarwala et al, 2004). Temozolomide is associated with a response
rate of 13–25% in the treatment of metastatic melanoma outside
the brain and is generally well tolerated with myelosuppression the
major toxicity (Bleehen et al, 1995; Middleton et al, 2000;
Bafaloukos et al, 2005; Kaufmann et al, 2005).
Lomustine (CCNU) is an orally administered nitrosurea that
crosses the blood brain barrier and has been used in combination
chemotherapy regimens such as ‘BOLD’ (bleomycin, vincristine,
lomustine, dacarbazine) in metastatic melanoma (Vuoristo et al,
1994; Punt et al, 1997; Vuoristo et al, 2005). Trials of a related
compound, fotemustine, have reported response rates of 5–25% in
melanoma metastatic to the brain (Jacquillat et al, 1990; Mornex
et al, 2003; Avril et al, 2004) and fotemustine has also been given in
combination with dacarbazine (Avril et al, 1990; Merimsky et al,
1992; Lee et al, 1993; Chang et al, 1994; Comella et al, 1997;
Richard et al, 1998; Seeber et al, 1998) and with temozolomide
(Marzolini et al, 1998; Gander et al, 1999). These drug combina-
tions are generally well tolerated although unexpected pulmonary
toxicity was reported in two studies of the combination of
dacarbazine and fotemustine (Gerard et al, 1993; Lee et al, 1993).
Pulmonary toxicity has also been reported in two other combina-
tion studies of alkylating agents in melanoma: two of 17 patients in
a study of carmustine and streptozocin developed fatal pulmonary
toxicity (Smith et al, 1996) while three of 23 patients in a phase II
trial of the BOLD regiment developed pneumonitis (Nathan et al,
1997).
The primary mechanism of action of lomustine is the alkylation
of the O
6 position of guanine-containing bases in DNA and the
enzyme O
6-alkylguanine transferase mediates in vitro resistance to
both lomustine and temozolomide (Baer et al, 1993). Temozolo-
mide has been shown to deplete O
6-alkylguanine transferase both
in vitro (Lacal et al, 1996) and in vivo (Gander et al, 1999) and
there is a rationale, therefore, for combining lomustine and
temozolomide in melanoma metastatic to the brain. It should be
noted that if the predominant in vivo mechanism of temozolomide
resistance was mediated via O
6-alkylguanine transferase, the
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srepeated administration of temozolomide might be expected to
reverse resistance to its own activity, but this has not been
observed in the treatment of melanoma. There are no clinical data
reported for pharmacokinetic interaction between temozolomide
and lomustine although there is no interaction between temozo-
lomide and fotemustine (Marzolini et al, 1998).
Given the modest but definite active of temozolomide in the
treatment of brain metastases from melanoma and the possibility
of synergy between temozolomide and lomustine, a multicentre
phase I/II trial was conducted to determine the maximum tolerated
dose (MTD), safety and efficacy of the combination of these drugs.
PATIENTS AND METHODS
Patients
Patients were eligible for enrolment if they had histologically
confirmed primary or secondary malignant melanoma with
radiological evidence of brain metastases. In the phase II section
of the study, eligible patients had bi-dimensionally measurable
brain metastases of at least 2cm in size on either contrast-
enhanced CT or MRI. Previous systemic therapy was permitted
for the treatment of melanoma and patients must have recovered
from the effects of major surgery. Steroid therapy was permitted
provided the dose was stable for at least 1 week before the
administration of the trial treatment. Other inclusion criteria were:
age of at least 18 years, WHO performance status of 0 to 2, life
expectancy of 12 weeks or greater, adequate bone marrow function
(haemoglobin 410gdl
–1, absolute neutrophil count 41.5 10
9l
–1
and platelet count 4100 10
9l
 1), adequate renal function
(plasma creatinine o120mmoll
–1 or calculated creatinine clear-
ance 450mlmin
–1 and urea less than twice the laboratory upper
limit of normal (ULN)) and adequate hepatic function (total and
direct serum bilirubin o1.5 times laboratory ULN, alanine
aminotransferase , aspartate aminotransferase and alkaline phos-
phatase o2 times the laboratory ULN). All patients provided
written informed consent.
Exclusion criteria were systemic anticancer therapy within 4
weeks of study entry, prior fotemustine, lomustine or temozolo-
mide therapy, prior whole-brain irradiation, radiation therapy
given to 30% or more of the bone marrow, unresolved toxicities
from previous therapies, acute infection or other uncontrolled
medical co-morbidity, inability to take oral medication, poor
respiratory reserve due to either a large volume of pulmonary
metastases or coexisting medical conditions, previous or con-
current malignancies at other sites with the exception of surgically
treated carcinoma-in-situ of the uterine cervix and basal or
squamous cell carcinoma of the skin, pregnant or breastfeeding
females and potentially fertile subjects not using effective contra-
ception.
Study design and statistical methods
The trial recruited at three centres in Leeds and London, UK from
July 2000 to March 2003. Approval for the study was obtained from
the local Ethics Committees. In phase I of the trial, a standard
design was adopted. The first patient was entered at dose level 1
and observed for 4 weeks. When no acute, severe or irreversible
toxicity was observed, two more patients were entered at dose
level 1 at weekly intervals. If no dose-limiting toxicity (DLT) was
observed, the next patient was recruited to dose level 2 when the
first patient completed two cycles of treatment. If grade 3 or 4
toxicity other than alopecia or inadequately treated nausea or
vomiting was observed in two out of three patients, the dose level
below was expanded to six patients. The MTD was defined as
the dose level below the level at which two of three patients
experienced DLT, provided no more than two of the six
experienced DLT at that level. For phase II of the study, a Gehan
2 stage design (Gehan, 1961) was used. To detect a response rate of
15% with a probability of a type I error of 5% and a type II error of
10% required the enrolment of 21 patients in stage 1. In the event
that one or more responses were observed in stage 1, accrual would
continue with a boundary condition that at least five responses
had occurred by the time that 62 patients had been enroled. The
primary end point of phase I was the MTD of temozolomide and
lomustine and of phase II the response rate at the phase I MTD.
Secondary end points included progression-free and overall
survival. Statistical analyses for baseline demographics, response
rates and adverse events were descriptive and Kaplan–Meier
analysis was used for survival data.
Treatment
Temozolomide was administered orally on days 1–5 of a 28-day
cycle. Lomustine was administered orally on day 5 every 56
days,that is, on every alternate cycle of temozolomide. The doses of
temozolomide and lomustine were escalated in phase I of the study
as shown in Table 1. In phase II of the study, the dose administered
was the MTD as defined in phase I, subject to dose modification in
the event of toxicity as described below.
Dose modifications
Clinical toxicity was evaluated before the start of each cycle of
therapy and nadir haematological toxicity measured by full blood
count at days 15 and 21 of each cycle. Lung function testing was
performed at baseline and subsequently in the event of cough or
dyspnoea not explained by intercurrent illness for example,
pneumonia. Treatment was then withheld until interstitial
pneumonitis was excluded. Treatment was administered on day
1 of a cycle if the absolute neutrophil count was at least 1.5 10
9l
–1
and the platelet count at least 100 10
9l
–1. In the event that the
blood counts were below these thresholds, treatment was not given
and the blood count repeated after a week. If blood counts were
sufficient after a 1-week delay, treatment was continued as planned
but if a 2-week delay occurred, treatment was administered at one
dose level lower. In the event that blood counts had not recovered
after 2 weeks, treatment was stopped and DLT assumed. Dose-
limiting toxicity was also assumed in the event of grade 4
thrombocytopaenia of any duration, the need for platelet
transfusion, nadir neutropaenia for greater than 7 days or an
episode of febrile neutropaenia.
Toxicity and response assessments
Response assessments were made according to the WHO criteria.
Patients were evaluated for clinical response at the end of each
cycle of therapy and in the absence of evidence of progression or
significant toxicity, staging CT or MRI was repeated after the third
and sixth cycles of treatment. Treatment was discontinued in the
event of clinical or radiographic evidence of progressive disease
and the patient assessed for radiotherapy. In the absence of disease
progression and significant toxicity, six courses of therapy were
administered and the patient was assessed for radiotherapy.
Table 1 Dose escalation regime for temozolomide and lomustine
Temozolomide dose
(mgm
 2)
Lomustine dose
(mgm
 2)
Dose level Days 1 to 5 p.o. q 28 days Day 5 p.o. q 56 days
1 100 60
2 150 60
3 150 80
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Baseline patient characteristics are shown in Table 2. Median time
from the diagnosis of primary melanoma to brain metastases was
36 months (range 1–252 months) and median time from diagnosis
of brain metastases to trial entry was 1 month (range 1–8 months).
No DLTs occurred in the three patients treated at dose level 1 after
two cycles of therapy (Table 1). The first patient treated at dose
level 2 was admitted to hospital on day 26 of cycle 1 with a fever,
grade 3 anaemia, grade 4 neutropaenia and grade 4 thrombo-
cytopaenia. The patient recovered after treatment with antibiotics,
intravenous fluids, GCSF and blood products. The patient was
noted to be dyspnoeic; grade 3 pulmonary fibrosis was diagnosed
and the patient was withdrawn from the trial. No DLT was noted in
the next two patients recruited to dose level 2. The first patient
treated at dose level 3 had grade 3 thrombocytopaenia after cycle 1
resulting in a 2-week delay in administering cycle 2 of therapy but
experienced no other DLT. The next two patients recruited at this
dose level both developed grade 4 thrombocytopaenia and grade 4
neutropaenia. One of these patients bled into a brain metastasis
and subsequently died as a result of sepsis.
As a result of the DLT observed at dose level 3, dose level 2 was
expanded and three further patients were treated. Dose-limiting
toxicity in the form of grade 4 thrombocytopaenia was observed in
one of these patients and as a result the MTD was defined,
therefore, at dose level 2, that is, temozolomide 150mgm
–2 days
1–5 every 28 days and lomustine 60mgm
–2 on day 5 every 56
days.
Fourteen patients were subsequently treated at dose level 2 in
phase II of the study. For the purpose of the analyses of safety and
efficacy, data from these patients were combined with the six
patients treated at dose level 2 in phase I of the study to give a total
of 20 patients. The majority of patients (65%) received only one
cycle of therapy and only 10% of patients received more than two
cycles of therapy (Table 3). No responses to therapy were seen
(Table 4) although one patient received six cycles of therapy with
stable disease on brain imaging. The median time from starting
chemotherapy to death was 2 months with only two patients alive
at 1 year and one alive at last follow-up (58 months). Of the 13
patients that only received one cycle of therapy, two had
progressive disease outside the brain while five had progressive
disease within the brain; all were withdrawn from the study. The
remaining six patients were withdrawn from the study due to
toxicities arising as a result of treatment (Table 5). Three of these
patients died. Two patients with grade 4 thrombocytopaenia died
with intracerebral bleeding and a further patient died as a result of
pneumonia with grade 4 neutropaenia.
Myelosuppression was the major significant toxicity recorded:
30% of patients had grade 3 or 4 neutropaenia and 35% had grade
3 or 4 thrombocytopaenia (Table 5). Grade 3 or 4 haemorrhage
occurred in 20% of patients while 10% of patients had grade 3 or 4
sepsis. Grade 3 or 4 anaemia was reported in 10% of patients. Half
of patients reported mild or moderate fatigue and approximately
a third of patients had grade 1 or 2 constipation, nausea or
headache. One patient was diagnosed with pulmonary fibrosis as
described above.
DISCUSSION
The maximum-tolerated dose of temozolomide and lomustine was
defined in phase I of this study as temozolomide 150mgm
–2given
Table 2 Baseline patient characteristics
n %
Sex
Male 14 54
Female 12 46
Age/years
Median (range) 50 (27–63)
Time from diagnosis of melanoma to brain metastases/(months)
Median (range) 36 (1–252)
Time from diagnosis of brain metastases to trial entry/(months)
Median (range) 1 (1–8)
Prior therapies
Adjuvant immunotherapy 7 27
Radiosurgery 1 4
Resection of brain metastasis 1 4
None 17 65
Performance status
Median (range) 1 (0–2)
Table 3 Number of cycles of treatment administered at recommended
Phase II dose (dose level 2, n¼20 patients)
Number of cycles administered n %
11 3 6 5
25 2 5
31 5
4— —
5— —
61 5
Table 4 Outcomes of therapy at recommended Phase II dose (dose
level 2, n¼20 patients)
Outcome n%
Response to therapy 0 0
Completed six cycles of therapy 1 5
Progressive disease in brain 10 50
Progressive disease outside brain 3 15
Toxicity necessitating withdrawal from trial 6 30
Table 5 Toxicity at recommended Phase II dose (dose level 2, n¼20
patients)
All grades Grade 3–4
n (%) n (%)
Haematological
Thrombocytopaenia 11 (55) 7 (35)
Leucopaenia 6 (30) 6 (30)
Neutropaenia 6 (30) 6 (30)
Anaemia 5 (25) 2 (10)
Nonhaematological
Fatigue 10 (50) — ( )
Nausea 7 (35) 1 (5)
Constipation 6 (30) 1 (5)
Headache 5 (25) — ( )
Haemorrhage 5 (25) 4 (20)
Pain 2 (10) — ( )
Dyspnoea 2 (10) 1 (5)
Sepsis 2 (10) 2 (10)
Diarrhoea 1 (5) — ( )
Pulmonary fibrosis 1 (5) 1 (5)
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son days 1–5 every 28 days and lomustine 60mgm
–2given on day
5 every 56 days. The DLTs of a dose of 80mgm
–2of lomustine in
combination with 150mgm
–2 of temozolomide were thrombo-
cytopaenia and neutropaenia and even at 60mgm
–2 of lomustine
50% of patients experienced at least grade 2 thrombocytopaenia.
There have been no other reports of temozolomide administered
according to the standard 5 day schedule in combination with
lomustine. Since this study was completed, it has been reported
that in patients with malignant high grade glioma, temozolomide
can be administered at a dose of 75mgm
–2 per day continuously
for 28 days in combination with lomustine at a dose of 100mgm
–2
on day 1 every 56 days without excessive toxicity (Tafuto et al,
2006). It should be noted, however, that extended schedule
temozolomide administration is not standard therapy for meta-
static melanoma although an extended temozolomide schedule
is currently under investigation in a phase III study in metastatic
melanoma in comparison with dacarbazine (EORTC protocol
18032).
Twenty patients were treated in this study at the MTD of
temozolomide and lomustine. No responses to treatment were
observed and although only seven patients received two or more
cycles of therapy, it is unlikely that the combination of lomustine
and temozolomide has significant activity in melanoma with brain
metastases. Progressive disease (both within and outside the brain)
was the most common reason for discontinuing therapy after
only one cycle. This highlights both the difficulty of conducting
clinical trials in this patient group and the need for effective
treatment agents with a rapid onset of action. An important
observation in this study is that the median survival from starting
chemotherapy was 2 months, which emphasises the very poor
prognosis of patients with brain metastases from melanoma, even
with good performance status. This figure is similar to the median
overall survival of 3.2 months reported in the largest clinical trial
of patients (N¼151) with brain metastases from melanoma
reported to date (Agarwala et al, 2004). It could be argued that
restaging patients after three cycles of treatment (as opposed
to two cycles) in the study reported here may have underestimated
the response rate, but this would be true only for very short-lived
responses, which would be of questionable clinical significance.
It is also possible that the requirement that CNS lesions be at least
2cm in size in this study may have predisposed towards
large volume disease and the possibility of rapid clinical
progression. It may have been problematic including patients
in this study with small volume CNS disease, however, as many
clinicians might adopt an expectant policy in the absence of
symptoms in this situation. A further potential criticism of this
study is that O
6-alkylguanine transferase levels were not measured:
this would have been of interest despite the lack of activity of
temozolomide and lomustine, although this is a difficult patient
group to obtain serial tissue samples, given the frequency of
rapidly progressive disease.
Temozolomide remains under evaluation in a variety of settings
in phase II trials for the treatment of brain metastases from
melanoma. One strategy has been to combine temozolomide with
other agents; for example, the combination of extended schedule
temozolomide and thalidomide (Hwu et al, 2005) can be
administered safely and results in responses in just over 10% of
patients. A second strategy has been to combine temozolomide
with whole brain irradiation, the standard treatment for melanoma
metastatic to the brain (Margolin et al, 2002; Hofmann et al, 2006).
The administration of temozolomide according to both the
standard (Hofmann et al, 2006) and an extended (Margolin et al,
2002) schedule in combination with whole brain irradiation is
generally safe and well-tolerated, but results in responses in only
about 10% of patients.
In conclusion, the MTD of temozolomide and lomustine in
patients with brain metastases from melanoma is temozolomide
150mgm
-2 given on days 1–5 every 28 days and lomustine
60mgm
-2 given on day 5 every 56 days. This dose causes
significant myelosuppression in terms of thrombocytopaenia and
neutropaenia in approximately one-third of patients and does not
demonstrate activity in this setting. The further evaluation of the
combination of temozolomide and lomustine for the treatment of
brain metastases from melanoma therefore is not warranted.
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